Genmab Announces Q3 Net Sales of $2.5B for DARZALEX (Daratumumab)
Portfolio Pulse from Benzinga Newsdesk
Genmab A/S (NASDAQ:GMAB) announced Q3 net sales of $2.5B for DARZALEX (daratumumab), including sales of the subcutaneous product sold under the tradename DARZALEX FASPRO in the U.S. The sales were reported by Johnson & Johnson, with $1.37B in the U.S. and $1.13B in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen.
October 17, 2023 | 10:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genmab's Q3 net sales of DARZALEX reached $2.5B, indicating strong performance. This could positively impact the company's stock in the short term.
The announcement of strong Q3 net sales for DARZALEX indicates a positive financial performance for Genmab. This could lead to increased investor confidence and a potential rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100